FOR IMMEDIATE RELEASE
CPR Therapeutics Inc. has completed early-phase proof-of-principal studies of its integrated cardiopulmonary resuscitation (CPR) system. These studies, undertaken at the Halperin Cardiology Bioengineering Laboratory at the Johns Hopkins Hospital, confirmed the Company’s foundational concept that multiple CPR pump mechanisms can be combined to produce dramatic improvements in hemodynamics.
Norman Paradis MD, the Company’s Founder and CEO stated: “We are pleased that these early studies provided such a strong signal of efficacy. Hemodynamic improvements of this magnitude are unheard of in resuscitation research. They strongly indicate that we’re on the right track and that our human prototype system will have a positive clinical trial.” Dr. Paradis is an emergency medicine physician and Professor at the Geisel School of Medicine at Dartmouth.
Dr. Henry Halperin, the Company’s Chief Scientific Officer: “This is very exciting. While the hypothesis that multiple CPR pump mechanisms might be synergistically combined had face-validity, it is good to see actual data.” Dr. Halperin is a cardiologist and the David J. Carver Professor of Medicine at Johns Hopkins University.
In a widely used model of cardiac arrest, the Company’s multimodal CPR resulted in more than 50% improvements in indicators of vital organ perfusion.
Dr. Paradis added “improvements like this are predictive of significantly increased rates of successful resuscitation. We look forward to continuing with our prototype R&D and moving toward clinical trials.”
CPR Therapeutics Inc.
CPR Therapeutics Inc. is a seed-stage medical device company developing the next generation system for cardiopulmonary resuscitation.
Sudden cardiac arrest may be the largest single cause of death and years of lost life in Western countries. Improving the outcome of patients after cardiac arrest is one of the great unmet medical needs. Each year over 300,000 deaths occur following sudden cardiac arrest in the U.S. alone. Fifty years after the first description of modern cardiopulmonary resuscitation (CPR) survival is below 10%, and the standard-of-care for these patients remains manual chest compressions performed by rescuers with their hands.
CPR Therapeutics Inc. is developing the first advanced technology automated CPR system that integrates and synchronizes multiple technological innovations into a single system that can be easily applied under emergency conditions. This advanced technology multimodal CPR cannot be performed by humans. It will enhance blood flow and the efficacy of electrical countershock in ways previously only available in laboratory settings. This system will, for the first time, demonstrate clinically significant improved survival. Info@CPRTherapeutics.com
DISCLAIMER: The information provided pertaining to CPR Therapeutics Inc. (“CPR-T” or the “Company”), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws. Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and reliable, CPR-T and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and CPR-T expressly disclaims any and all liability that may be based on such information or errors or omissions thereof. CPR-T reserves the right toamend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amendedinformation or to notify the recipient thereof.